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OBJECTIVES This study reports the outcome of patients who failed intracoronary radiation therapy (IRT)
for the treatment of in-stent restenosis (ISR).
BACKGROUND Intracoronary radiation therapy has demonstrated a reduction in the recurrence rate of
restenosis for patients with ISR. However, 10% to 30% of these patients require repeat
intervention to the irradiated site.
METHODS Of 961 patients who were assigned to gamma or beta radiation for the treatment of diffuse
ISR, we evaluated the outcome of 282 (29%) consecutive patients who failed IRT and
compared them with the 679 (71%) patients who had successful IRT. For patients who failed
radiation, the mean time to the first target vessel revascularization (TVR) was 173 127 days
after the index procedure and the total duration of follow-up was 494  304 days.
RESULTS Patients who failed IRT were younger (60  10 vs. 63  11 years, p  0.002) and had a
higher incidence of restenting (51% vs. 41%, p 0.003). The majority (55%) of the restenotic
lesions after IRT failure were focal (10 mm), with a mean lesion length of 11.9  1.9 mm.
Of the 257 patients who had subsequent TVR after failed IRT, 68 (26%) underwent coronary
artery bypass grafting and 189 (74%) underwent percutaneous coronary intervention using
balloon in 61%, restenting in 26%, atheroablation in 11%, and the cutting balloon in 2% of
cases. At six months, 6% of patients died, 1% had Q-wave MI, 17% had repeat TVR, and the
overall rate of major adverse cardiac events was 21%.
CONCLUSIONS The predominant angiographic pattern of lesions in patients who failed IRT is focal
restenosis, with these lesions responding well to conventional revascularization
methods. (J Am Coll Cardiol 2003;41:551–6) © 2003 by the American College of
Cardiology Foundation
Restenosis after stent implantation can be predicted by a
number of variables, including vessel size, post-procedural
percent diameter stenosis, and stent length (1,2). In-stent
restenosis (ISR) represents a clinical entity of striking
magnitude, and is likely to become more prevalent as
coronary stenting continues its widespread application (3).
Intracoronary radiation therapy (IRT) using both gamma
and beta emitters has demonstrated a reduction in the
recurrence rate of restenosis for patients with ISR of native
coronary arteries and saphenous vein grafts (4–9). However,
10% to 30% of these patients require repeat intervention to
the irradiated site, which occurs either within the stented
segment or involves edge restenosis (10). Although the rate
of recurrent restenosis after IRT has been established, the
nature of this restenotic process (i.e., focal vs. diffuse,
in-stent vs. edge) has been inadequately characterized. In
addition, factors that predict radiation failure are unknown.
The aim of this study was to report clinical and angio-
graphic outcomes of patients who failed IRT, defined as
patients who required repeat target vessel revascularization
(TVR) after IRT (either by percutaneous coronary inter-
vention [PCI] or coronary artery bypass grafting [CABG]),
or patients with subsequent total occlusion at the irradiated
lesion who were managed medically.
METHODS
Selection of patients. We analyzed 961 consecutive pa-
tients enrolled in the Washington Radiation for In-Stent
restenosis Trial (WRIST) series of radiation trials for ISR
using gamma and beta emitters at the Washington Hospital
Center between February 1997 and March 2001. These
trials were designed to test the effectiveness of IRT as an
adjunctive treatment to the conventional intervention of
ISR. The study population included patients treated with
IRT who had completed at least six months of clinical
follow-up.
All studies involved an Investigational Device Exemption
granted by the Food and Drug Administration, and were
approved by the Institutional Review Board and the Radi-
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ation Safety Committee at the Washington Hospital Cen-
ter. Informed consent was obtained for all patients. All
clinical events were independently adjudicated by an exter-
nal committee.
The inclusion criteria for the initial IRT index procedure
included ISR, lesion diameter stenosis 50% in the pres-
ence of angina or inducible ischemia on functional testing,
reference vessel diameter 2.5 to 5.0 mm, lesion length 80
mm, and successful primary coronary intervention. Exclu-
sion criteria included acute myocardial infarction (MI)
within 72 h of the index procedure, left ventricular ejection
fraction 20%, angiographic visible thrombus, multiple
coronary lesions, and previous coronary or chest radiation
therapy.
Procedural protocol. Before the percutaneous coronary
artery or saphenous vein graft intervention, an angiogram
and an intravascular ultrasound study were performed to
determine lesion length and vessel size. Percutaneous inter-
vention was performed with conventional or cutting balloon
dilation, excimer laser, rotational atherectomy, and/or re-
stenting. In preparation for IRT treatment, the patient was
further sedated, with the activated clotting time maintained
at 300 s with intravenous heparin.
The gamma (192-Iridium) and beta (90-Yttrium) IRT
treatments in the WRIST studies have been previously
described (4,6). Accurate positioning of the source train was
documented by angiography; at least 4-mm overlap of
normal segments on each end of the ISR was employed to
limit edge restenosis. A radiation oncologist was responsible
for handling the radiation source, a radiation physicist was
integral in dose calculation, and a radiation safety officer
ensured that adequate safety precautions were undertaken
during the radiation dwelling period.
A final angiogram was performed, and if required, further
intervention was undertaken to optimize the final results.
Routine post-PCI care included cessation of heparin, early
sheath removal, and, in addition to aspirin, antiplatelet
therapy with either ticlopidine 250 mg orally twice daily or
clopidogrel 75 mg daily for one to six months (depending on
the study protocol).
Study end points. Target lesion revascularization (TLR
[site of the injured and irradiated segment at the index
procedure]) and TVR (any part of the treated vessel includ-
ing the site of the initial injured and irradiated segment)
consisted of repeat PCI or CABG, driven by clinical signs
of ischemia in the presence of angiographic restenosis.
The specific focus of this study was to analyze the efficacy
of repeat revascularization procedures after failed IRT. This
was defined as the need for TVR at any time period beyond
the index radiation procedure or patients with total occlu-
sion of the target lesion on routine follow-up angiography
who were managed medically. The need for additional TVR
was also analyzed, including the time interval between
interventions and the type of revascularization strategy
performed (PCI or CABG). Major adverse cardiac events
(MACE) were defined as death, Q-wave MI, or TVR. Late
total occlusion was defined as angiographically documented
total occlusion at the lesion site at least 30 days after the
index IRT procedure.
Angiographic analysis. The Washington Hospital Center
angiographic core laboratory performed quantitative an-
giography using the CMS-GFT system (Medis, Leiden,
Netherlands). Angiographic analysis was performed on the
angiogram of patients requiring percutaneous reintervention
of the target lesion, and a comparison was made to the
angiogram of the index procedure. The minimal luminal
diameter was determined for the total analyzed segment (5
mm proximal and distal to the irradiated segment). The
reference vessel diameter and pre- and post-procedural
diameter stenoses after the intervention were calculated.
Edge restenosis was defined as a follow-up diameter stenosis
50% of the reference vessel diameter within 5 mm of the
proximal or distal irradiated zone.
Statistical analysis. In comparing patients who failed ra-
diation with those who did not, continuous variables were
expressed as means  SD and categorical data were ex-
pressed as percentages. Student t test was used to compare
continuous variables; chi-square statistics or Fisher exact
test was used to compare categorical values. A stepwise
logistic regression analysis was performed to determine
independent predictors of radiation failure. The variables
used in this analysis included the following: index procedure
variables; type of radiation (gamma or beta); age; gender;
hypertension; diabetes; history of smoking; hypercholester-
olemia; history of MI; history of CABG; history of PCI;
unstable angina; multivessel disease; pre- and post-minimal
luminal diameter; lesion length; reference vessel diameter;
left ventricular ejection fraction; coronary vessel treated; and
the initial treatment strategy, which included balloon an-
gioplasty alone, excimer laser coronary angioplasty, rota-
tional atherectomy, or restenting. Independent variables
were expressed as odds ratio (OR) with 95% confidence
intervals (CI). A value of p  0.05 was considered statisti-
cally significant.
RESULTS
Characteristics of study population. A total of 961 con-
secutive IRT patients (mean follow-up 494  304 days)
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were analyzed, and 282 (29%) IRT failure patients were
identified (Fig. 1). The baseline characteristics of patients
are displayed in Table 1. Of the IRT failures, 25 patients
had total occlusion at the irradiated site and were managed
medically (4 patients in this group had subsequent percuta-
neous laser myocardial revascularization therapy). The ma-
jority, 257 (91%), underwent TVR (mean time to first TVR
was 173  127 days after the index procedure).
Of the total cohort, 911 patients (95%) were enrolled in
gamma radiation trials for ISR and 50 patients (5%)
received beta radiation for ISR (Table 2). Twenty-nine
percent of patients receiving gamma radiation failed, and
30% of patients receiving beta radiation failed (p  NS).
Patients who failed IRT were younger (60 10 vs. 63 11
years, p  0.002) and more likely to have required restent-
ing at the index procedure (51% vs. 41%, p  0.003),
compared with patients who had successful IRT. A total of
74 patients (26% of 282) had angiographic late total
occlusion diagnosed at the time of IRT failure. Late
thrombosis (late total occlusion with a clinical event) was
identified in 28 of these patients, i.e., 38% of the late total
occlusion population.
In-hospital outcomes for first TVR after failed radiation
therapy. The procedural success rate of the first TVR after
failed radiation therapy was 96% for patients treated with
PCI. Sixty percent of patients required TLR at the time of
IRT failure. No coronary perforations were identified, and
14% of patients had a post-procedural creatine kinase rise to
3 times baseline. There were no in-hospital deaths or
Q-wave MI, and 4% of patients underwent repeat in-
hospital PCI.
In patients who underwent TVR with PCI, conventional
balloon angioplasty was used in 61% of patients, restenting
in 26%, atheroablation (rotablation or excimer laser) in 11%,
and cutting balloon in 2%.
Angiographic results for first TVR after failed radiation
therapy. Quantitative coronary angiography performed on
the PCI for first TVR after failed radiation therapy dem-
onstrated that the majority of recurrent ISR lesions were
relatively short, with a mean lesion length of 11.9 1.9 mm
(Table 3). Fifty-five percent of these restenotic lesions were
focal (10 mm). Analysis of diffuse lesions at index IRT
revealed a 50% reduction in lesion length at subsequent first
TVR after failed IRT (28.5  13.5 mm at index IRT vs.
14.4 7.5 mm at time of TVR for IRT failure, p 0.001).
Edge restenosis was identified as the site of failure in 18% of
cases. Thirty-two patients of the IRT failure group who had
TVR (12% of 257 patients) had total occlusion ISR at the
Table 1. Baseline Clinical Characteristics of Total Cohort at Index Procedure
Characteristic
Failed IRT
(N  282)
Successful IRT
(N  679) p
Age (yrs) 60  10 63  11 0.002
Gender male (%) 65 68 NS
Previous MI (%) 57 52 NS
History of 1 treatment for ISR (%) 53 56 NS
Diabetes (%) 40 43 NS
Hypertension (%) 78 73 NS
Hypercholesterolemia (%) 89 87 NS
Multivessel disease (%) 55 57 NS
Left ventricular ejection fraction 0.47  0.12 0.49  0.13 NS
Lesion length (mm) 23.8  12.5 22.3  11.8 NS
Reference vessel diameter (mm) 2.7  0.4 2.8  0.5 NS
Vessels treated (%)
Left anterior descending artery 23 23 NS
Left circumflex artery 23 24 NS
Right coronary artery 28 27 NS
Saphenous vein graft 21 22 NS
Treatment strategy at index procedure (%)
Balloon alone 14 17 NS
Excimer laser coronary angioplasty 30 26 NS
Rotational atherectomy 42 41 NS
Restenting 51 41 0.003
*Hypercholesterolemia (patient on cholesterol-lowering therapy or total cholesterol 200 mg/dl).
IRT  intracoronary radiation therapy; ISR  in-stent restenosis; MI  myocardial infarction; NS  not significant.
Figure 1. Study population defined by outcome after intracoronary radia-
tion therapy (IRT). CABG  coronary artery bypass grafting; PCI 
percutaneous coronary intervention; TVR target vessel revascularization.
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index procedure, 8 (25%) of whom returned with total
occlusion at the time of IRT failure.
The reference vessel diameter of the radiation failures was
2.65  0.49 mm, and the pre- and post-intervention
minimal luminal diameter were 0.86  0.74 mm and 1.87
 0.43 mm, respectively. The diameter stenosis improved
from 67  27% preintervention to 20  15% post-
intervention.
Late outcomes of radiation failure patients. Of the 257
patients who required TVR, 68 (26%) underwent CABG
and 189 (74%) underwent PCI. Additional TVR was
required in 3% of patients in the CABG group and 32% of
patients in the PCI group (mean period between first and
second TVR was 152  108 days).
At six months follow-up after IRT failure of 282 patients,
15 patients (5%) died and 3 patients (1%) sustained a
Q-wave MI (Table 4). The etiology of the 15 deaths are as
follows: 4 late thromboses (all patients had ceased clopi-
dogrel at the time of the clinical event), 5 MI (distribution
consistent with non-irradiated vessel), 5 congestive cardiac
failures, and 1 major ischemic stroke. Twenty-six patients
required TLR (9%), 47 (17%) required TVR, and the
overall MACE rate was 21%.
The only independent predictor of IRT failure on mul-
tivariate analysis was restenting at the index IRT procedure
(OR 1.54, CI 1.15 to 2.06, p  0.035).
DISCUSSION
The principal findings of this study include the following: 1)
the rate of failed IRT was 29% (of 961 patients) at a mean
follow-up of 494  304 days; 2) in patients failing IRT, the
majority (91%) underwent repeat TVR; 3) in the majority of
these cases, PCI was the preferred method of revasculariza-
tion (74% overall), and in these cases, conventional balloon
dilation was used most frequently (61%); 4) the predomi-
nant pattern of recurrence was focal restenosis (55%), with
an overall mean lesion length of 11.9  1.9 mm; 5) edge
restenosis was detected in 18%; 6) at six months follow-up
after confirmed IRT failure, the rate of subsequent TVR
was 17% and MACE was 21%; 7) the rate of recurrent TVR
was 32% in patients with radiation failure treated with
repeat PCI (mean time interval between first and second
TVR of 152  108 days); and 8) restenting was an
independent predictor of failed IRT.
The etiology of failed IRT is poorly understood. One
explanation may be underdosing. A subset of patients may
require a higher radiation dose than prescribed by conven-
tional protocols. In Long WRIST High Dose (11) (18 Gy
delivered at 2 mm), the six-month TVR rate was 17%
compared with 33% in irradiated patients of Long WRIST
(11) ([15 Gy at 2 mm], p  0.001). Moreover, intravascular
ultrasound analysis in the same cohorts showed that despite
longer ISR lesions, Long WRIST High Dose had a greater
minimum lumen area (4.0  1.4 mm2) compared with the
Table 2. Radiation Failure Patients According to IRT Study
Study Name (Ref.) Isotope
No. of IRT
Patients
(n  961)
Mean Follow-Up
(days)
No. of IRT
Failure Patients
(n  282)
% Failure
Within Study
WRIST (4) 192-Iridium 65 953  660 28 43
Long WRIST (11) 192-Iridium 60 606  370 32 53
Long WRIST High Dose (11) 192-Iridium 120 404  230 32 27
SVG WRIST (9) 192-Iridium 60 904  319 20 33
WRIST Plus (12) 192-Iridium 120 400  135 42 35
Compassionate WRIST (20) 192-Iridium 199 409  233 61 31
WRIST 12 (20) 192-Iridium 120 434  668 20 17
WRIST cross-over* (20) 192-Iridium 91 719  369 22 28
Integrilin WRIST (20) 192-Iridium 76 117  92 10 13
Beta WRIST (6) 90-Yttrium 50 890  316 15 30
*WRIST cross-over includes patients who were initially assigned placebo therapy in randomized trials of WRIST, SVG WRIST, and Long WRIST and were subsequently
treated with IRT.
IRT  intracoronary radiation therapy; SVG  saphenous vein graft; WRIST  Washington Radiation for In-Stent restenosis Trial.
Table 3. Angiographic Characteristics of PCI at TVR for
Patients Failing Radiation (n  189)
Reference vessel diameter (mm) 2.65  0.49
Minimal luminal diameter (mm)
Pre 0.86  0.74
Post 1.87  0.43
Diameter stenosis (%)
Pre 67  27
Post 20  15
Lesion length (mm) 11.9  1.9
Pattern of restenosis (%)
Focal 55
Diffuse 45
Edge 18
PCI  percutaneous coronary intervention; TVR  target vessel revascularization.
Table 4. Clinical Events Six Months after Radiation Failure
(n  282)
Clinical Event
No. of Clinical Events
(%)
Death 15 (6)
Q-wave MI 3 (1)
Non–Q-wave MI 5 (2)
TLR 26 (9)
TVR 47 (17)
MACE 58 (21)
MACE  major adverse cardiac events; MI  myocardial infarction; TLR  target
lesion revascularization; TVR  target vessel revascularization.
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irradiated patients of Long WRIST (2.9  1.0 mm2, p 
0.005) (11).
A second explanation for IRT failure is late thrombosis,
which has recently been reported to be controlled with
prolonged antiplatelet therapy (12). Thirdly, inadequate
coverage of the treated lesions with radiation may lead to
geographic miss; a cause of recurrence at the edge of the
radiation field known as edge effect (10). Specific analysis
for “geographic miss” was not performed in this study,
although it has been previously shown in the first (original)
WRIST (65 patients from this cohort) to be a confounding
contributor to radiation failure (10). Eighteen percent of
cases requiring repeat TVR after IRT were due to edge
restenosis, an entity that remains poorly understood. Edge
restenosis may be related to the radiation source train not
fully covering the injured segment (a combination of injury
and low-dose IRT) (13). A longer radiation source train has
been proposed to ensure that the injured vessel is suitably
irradiated. However, in the START 40/20 trial, the rate of
TVR was not reduced by lengthening the source train (40
mm) compared with the IRT patients of START (14).
In the cohort of IRT failures who underwent TVR,
conventional balloon angioplasty was favored among a
variety of treatment strategies available for the treatment of
ISR. Balloon angioplasty has traditionally been preferred for
focal lesions, and atheroablation therapy has been preferred
for diffuse ISR lesions (15–17). Restenting has been used to
treat edge dissection and to prevent tissue prolapse in an
attempt to optimize final luminal area. Despite theoretical
advantages, no approach has proved superior, and the
recurrence rate of ISR without IRT remains high (50%),
whichever technique is used. In patients receiving adjunctive
IRT for ISR, the device used did not influence clinical
outcomes (18). The cutting balloon has gained popularity
for ISR with recent reports of less late loss and reduced
restenosis, although it has not been tested with IRT (19).
The cutting balloon limits “watermelon” seeding and thus
potentially reduces balloon injury length.
This study reflects a contemporary series of IRT patients
spanning over four years. The highest percentage of IRT
failures per study was found in the earliest trials such as
WRIST (43%) and Long WRIST (53%). In this period of
time, significant advances have been made in the under-
standing of IRT, particularly the need for prolonged anti-
platelet therapy, the need for longer source trains, avoidance
of restenting, and the benefits of higher dosing (10,12).
Although we did not control for these factors in the current
study, they appear to have contributed to the reduced failure
rate seen in Long WRIST High Dose (27%) and WRIST
12 (20) (17%).
The type of emitter (gamma or beta) did not influence
IRT failure in our cohort. This observation is interpreted
with caution as this study was not designed to assess
differences in emitters, and the number of patients in the
beta cohort was relatively small.
In terms of treatment guidelines, we now believe it is
essential to limit restenting at the time of index radiation, to
ensure an adequate radiation treatment margin, and to
administer at least 12 months antiplatelet therapy (clopi-
dogrel) in addition to aspirin. The role of drug-eluting
stents for this population remains ill-defined.
Study limitations. This study has the inherent limitations
of a retrospective design. However, the data were collected
prospectively and adjudicated independently. The majority
of patients enrolled in radiation trials had routine angio-
graphic follow-up. We estimate that approximately 10% to
15% of patients had TVR performed on angiographic
criteria (oculo-stenotic reflex of the operator), not driven by
cardiac symptoms or functional testing, which may have
overestimated the true failure rate.
Conclusions. Our initial experience with IRT for ISR
suggests a failure rate of 29%. The predominant angio-
graphic pattern of these lesions is focal, responding well to
conventional revascularization methods (PCI and cardiac
bypass grafting). We anticipate that the implementation of
various therapeutic modifications associated with the radi-
ation procedure (e.g. dosing, antiplatelet therapy) will fur-
ther reduce the need for TVR in this complex patient
population.
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